HK1057864A1 - Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders. - Google Patents

Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.

Info

Publication number
HK1057864A1
HK1057864A1 HK04100730A HK04100730A HK1057864A1 HK 1057864 A1 HK1057864 A1 HK 1057864A1 HK 04100730 A HK04100730 A HK 04100730A HK 04100730 A HK04100730 A HK 04100730A HK 1057864 A1 HK1057864 A1 HK 1057864A1
Authority
HK
Hong Kong
Prior art keywords
cns
disorders
preparation
nervous system
central nervous
Prior art date
Application number
HK04100730A
Other languages
English (en)
Inventor
Wayne Everett Childers
Michael Gerard Kelly
Sharon Joy Rosenzweig-Lipson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HK1057864A1 publication Critical patent/HK1057864A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
HK04100730A 2000-11-28 2004-02-04 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders. HK1057864A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25330100P 2000-11-28 2000-11-28
US29781401P 2001-06-13 2001-06-13
PCT/US2001/043160 WO2002044142A2 (en) 2000-11-28 2001-11-27 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders

Publications (1)

Publication Number Publication Date
HK1057864A1 true HK1057864A1 (en) 2004-04-23

Family

ID=26943115

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100730A HK1057864A1 (en) 2000-11-28 2004-02-04 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.

Country Status (25)

Country Link
US (3) US6469007B2 (ru)
EP (1) EP1339406B1 (ru)
JP (1) JP4198989B2 (ru)
KR (1) KR100835552B1 (ru)
CN (1) CN100352437C (ru)
AR (1) AR035603A1 (ru)
AT (1) ATE269078T1 (ru)
AU (2) AU2002237654B2 (ru)
BR (1) BR0115609A (ru)
CA (1) CA2428039C (ru)
DE (1) DE60103927T2 (ru)
DK (1) DK1339406T3 (ru)
EA (1) EA005925B1 (ru)
ES (1) ES2222401T3 (ru)
HK (1) HK1057864A1 (ru)
HU (1) HUP0400551A2 (ru)
IL (1) IL156098A0 (ru)
MX (1) MXPA03004677A (ru)
NO (1) NO325501B1 (ru)
NZ (1) NZ526150A (ru)
PL (1) PL363219A1 (ru)
PT (1) PT1339406E (ru)
TR (1) TR200401546T4 (ru)
TW (1) TWI224102B (ru)
WO (1) WO2002044142A2 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
CN101492383A (zh) 2002-03-12 2009-07-29 惠氏公司 制备手性1,4-二取代哌嗪的方法
US7091349B2 (en) 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
US7361773B2 (en) 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
CN1982307A (zh) 2002-03-12 2007-06-20 惠氏公司 合成手性n－芳基哌嗪的方法
GB0219961D0 (en) * 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
PA8626301A1 (es) * 2004-03-19 2006-12-07 Wyeth Wyeth Proceso para preparar derivados de n-aril-piperazina
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
KR100646337B1 (ko) * 2004-06-30 2006-11-23 주식회사 롯데기공 보일러의 누수 감지방법
WO2006044596A2 (en) 2004-10-15 2006-04-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
US20070027162A1 (en) * 2005-03-01 2007-02-01 Wyeth Crystalline and amorphous 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
JP2008543867A (ja) * 2005-06-17 2008-12-04 ワイス セロトニン阻害剤ならびに５−ｈｔ１ａアゴニストおよびアンタゴニストとして有用な三環系化合物
WO2007089616A2 (en) * 2006-01-26 2007-08-09 The University Of Rochester Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
CL2008000119A1 (es) * 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives

Also Published As

Publication number Publication date
NO20032390L (no) 2003-07-22
TR200401546T4 (tr) 2004-09-21
AR035603A1 (es) 2004-06-16
NO20032390D0 (no) 2003-05-27
CA2428039A1 (en) 2002-06-06
AU3765402A (en) 2002-06-11
US20030022901A1 (en) 2003-01-30
ES2222401T3 (es) 2005-02-01
HUP0400551A2 (en) 2006-02-28
CN100352437C (zh) 2007-12-05
IL156098A0 (en) 2003-12-23
DE60103927D1 (de) 2004-07-22
WO2002044142A2 (en) 2002-06-06
EA005925B1 (ru) 2005-08-25
US6586436B2 (en) 2003-07-01
PT1339406E (pt) 2004-10-29
US20030216408A1 (en) 2003-11-20
EA200300619A1 (ru) 2003-10-30
KR20030051879A (ko) 2003-06-25
EP1339406B1 (en) 2004-06-16
PL363219A1 (en) 2004-11-15
CA2428039C (en) 2011-08-09
BR0115609A (pt) 2003-11-11
JP2004520289A (ja) 2004-07-08
DE60103927T2 (de) 2005-06-23
US6469007B2 (en) 2002-10-22
JP4198989B2 (ja) 2008-12-17
KR100835552B1 (ko) 2008-06-09
EP1339406A2 (en) 2003-09-03
MXPA03004677A (es) 2003-09-05
NO325501B1 (no) 2008-05-26
US20020107254A1 (en) 2002-08-08
US7026320B2 (en) 2006-04-11
DK1339406T3 (da) 2004-09-27
CN1477961A (zh) 2004-02-25
WO2002044142A3 (en) 2002-08-08
NZ526150A (en) 2004-11-26
ATE269078T1 (de) 2004-07-15
AU2002237654B2 (en) 2005-07-28
TWI224102B (en) 2004-11-21

Similar Documents

Publication Publication Date Title
HK1057864A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.
PL373626A1 (en) Treatment for central nervous system disorders
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
MXPA02008801A (es) Derivados de indol, proceso para la preparacion de los mismos y su uso.
AU2002212226A1 (en) Use of indole derivatives for treating illnesses of the central nervous system
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
ZA200300411B (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.
HK1047871A1 (en) Apparatus and methods for making multiple, complexly patterned extrudates.
HUP0203425A3 (en) Quinazoline derivatives, process for their preparation and their use
ZA200202542B (en) Treating sleep disorders using desloratadine.
SI0908458T1 (sl) Substituirani piridilmetilpiperazinovi in piperidinovi derivati, njihova priprava in njihova uporaba za zdravljenje motenj centralnega zivcnega sistema (cns)
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
HUP0303568A3 (en) Benzothiophene derivatives, process for their preparation and use thereof
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
MXPA03000574A (es) Vidrios ceramizados, proceso para su preparacion y uso.
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
GB0015228D0 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
SI1339406T1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091127